Efanesoctocog Alfa PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
2252477-42-0
Molecular formula
C13690H20958N3682O4376S136
Molecular weight
Not available
Drug class
Extended-half-life recombinant human coagulation factor VIII (Fc–VWF–XTEN fusion protein)
Mechanism of action
Replaces deficient factor VIII in haemophilia A. Activated factor VIII functions as a cofactor for activated factor IX in the tenase complex, accelerating factor X activation and thrombin generation.
Indications / reported uses
Treatment and prophylaxis of bleeding in congenital haemophilia A (factor VIII deficiency), across age groups under the cited EMA product information
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Efanesoctocog Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Efanesoctocog Alfa Permitted Daily Exposure (PDE) report (the Efanesoctocog Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Efanesoctocog Alfa Occupational Exposure Limit (OEL) report (the Efanesoctocog Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.